ASH 2021: Patients With Lymphoid and Myeloid Disease Are at Risk of Poor Response to COVID-19 Vaccination
Use of Bruton’s tyrosine kinase inhibitors, immunoglobulins, rituximab, and ruxolitinib are all associated with low seroconversion rate
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.